185 related articles for article (PubMed ID: 26723876)
1. Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
Hwang JE; Joung JY; Shin SP; Choi MK; Kim JE; Kim YH; Park WS; Lee SJ; Lee KH
Cancer Lett; 2016 Mar; 372(1):57-64. PubMed ID: 26723876
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
[TBL] [Abstract][Full Text] [Related]
3. Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
Cho H; Byun SS; Son NH; Chung JI; Seo WI; Lee CH; Morgan TM; Han KH; Chung JS
Clin Cancer Res; 2024 May; 30(9):1788-1800. PubMed ID: 38587547
[TBL] [Abstract][Full Text] [Related]
4. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T
Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL.
Jiménez JA; Li X; Zhang YP; Bae KH; Mohammadi Y; Pandya P; Kao C; Gardner TA
Cancer Gene Ther; 2010 Mar; 17(3):180-91. PubMed ID: 19798123
[TBL] [Abstract][Full Text] [Related]
8. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
9. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
Ben Jemaa A; Sallami S; Céraline J; Oueslati R
Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
Paller CJ; Piana D; Eshleman JR; Riel S; Denmeade SR; Isaacsson Velho P; Rowe SP; Pomper MG; Antonarakis ES; Luo J; Eisenberger MA
Prostate; 2019 Oct; 79(14):1597-1603. PubMed ID: 31361358
[TBL] [Abstract][Full Text] [Related]
11. Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy.
Yates DR; Rouprêt M; Drouin SJ; Comperat E; Ricci S; Lacave R; Sèbe P; Cancel-Tassin G; Bitker MO; Cussenot O
Prostate; 2012 Sep; 72(12):1382-8. PubMed ID: 22228175
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
[TBL] [Abstract][Full Text] [Related]
13. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.
Zeng H; Wei Q; Huang R; Chen N; Dong Q; Yang Y; Zhou Q
J Androl; 2007; 28(6):827-35. PubMed ID: 17522418
[TBL] [Abstract][Full Text] [Related]
14. Antihormone treatment differentially regulates PSA secretion, PSMA expression and
Mathy CS; Mayr T; Kürpig S; Meisenheimer M; Dolscheid-Pommerich RC; Stoffel-Wagner B; Kristiansen G; Essler M; Muders MH; Bundschuh RA
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1733-1743. PubMed ID: 33760944
[TBL] [Abstract][Full Text] [Related]
15. Novel prostate-specific promoter derived from PSA and PSMA enhancers.
Lee SJ; Kim HS; Yu R; Lee K; Gardner TA; Jung C; Jeng MH; Yeung F; Cheng L; Kao C
Mol Ther; 2002 Sep; 6(3):415-21. PubMed ID: 12231179
[TBL] [Abstract][Full Text] [Related]
16. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
Yu DC; Sakamoto GT; Henderson DR
Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Nagaya N; Nagata M; Lu Y; Kanayama M; Hou Q; Hotta ZU; China T; Kitamura K; Matsushita K; Isotani S; Muto S; Sakamoto Y; Horie S
PLoS One; 2020; 15(1):e0226219. PubMed ID: 31986176
[TBL] [Abstract][Full Text] [Related]
18. Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model.
Dzojic H; Cheng WS; Essand M
Cancer Gene Ther; 2007 Mar; 14(3):233-40. PubMed ID: 17053814
[TBL] [Abstract][Full Text] [Related]
19. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
Li X; Liu YH; Zhang YP; Zhang S; Pu X; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5463-73. PubMed ID: 17875776
[TBL] [Abstract][Full Text] [Related]
20. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
